company background image
PRQR logo

ProQR Therapeutics NasdaqCM:PRQR Stock Report

Last Price

US$2.42

Market Cap

US$270.4m

7D

-12.3%

1Y

8.5%

Updated

10 Jan, 2025

Data

Company Financials +

ProQR Therapeutics N.V.

NasdaqCM:PRQR Stock Report

Market Cap: US$270.4m

PRQR Stock Overview

A biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More details

PRQR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 42.64% per year

Earnings have grown 9.9% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

ProQR Therapeutics N.V. Competitors

Foghorn Therapeutics

NasdaqGM:FHTX

US$258.5m

Voyager Therapeutics

NasdaqGS:VYGR

US$313.0m

Ocugen

NasdaqCM:OCGN

US$242.1m

Orchard Therapeutics

NasdaqCM:ORTX

US$380.1m

Price History & Performance

Summary of share price highs, lows and changes for ProQR Therapeutics
Historical stock prices
Current Share PriceUS$2.42
52 Week HighUS$4.62
52 Week LowUS$1.61
Beta0.30
1 Month Change-28.40%
3 Month Change30.81%
1 Year Change8.52%
3 Year Change-64.20%
5 Year Change-69.90%
Change since IPO-83.57%

Recent News & Updates

Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding

Dec 14
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding

Recent updates

Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding

Dec 14
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Apr 03
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Nov 28
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Jul 30
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Shareholder Returns

PRQRUS BiotechsUS Market
7D-12.3%-2.4%-2.1%
1Y8.5%-8.7%21.3%

Return vs Industry: PRQR exceeded the US Biotechs industry which returned -6.4% over the past year.

Return vs Market: PRQR underperformed the US Market which returned 23.2% over the past year.

Price Volatility

Is PRQR's price volatile compared to industry and market?
PRQR volatility
PRQR Average Weekly Movement36.8%
Biotechs Industry Average Movement11.2%
Market Average Movement6.4%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: PRQR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PRQR's weekly volatility has increased from 20% to 37% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012157Daniel de Boerwww.proqr.com

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.

ProQR Therapeutics N.V. Fundamentals Summary

How do ProQR Therapeutics's earnings and revenue compare to its market cap?
PRQR fundamental statistics
Market capUS$270.39m
Earnings (TTM)-US$24.53m
Revenue (TTM)US$18.84m

13.3x

P/S Ratio

-10.2x

P/E Ratio

Is PRQR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRQR income statement (TTM)
Revenue€18.39m
Cost of Revenue€0
Gross Profit€18.39m
Other Expenses€42.33m
Earnings-€23.94m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.23
Gross Margin100.00%
Net Profit Margin-130.21%
Debt/Equity Ratio18.1%

How did PRQR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 05:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ProQR Therapeutics N.V. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Eliana MerleCantor Fitzgerald & Co.
Steven SeedhouseCGS International